Determinants of durable humoral and T cell immunity in myeloma patients following <scp>COVID</scp>‐19 vaccination-Reference-Cited by-同舟云学术

Determinants of durable humoral and T cell immunity in myeloma patients following COVID‐19 vaccination

Published:2023-12-20 Issue: Volume: Page:
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Twumasi Clement¹²^ORCID,Moore Sally³^ORCID,Sadler Ross⁴^ORCID,Jeans Sally⁵,Varghese Sherin⁴^ORCID,Turner Alison²^ORCID,Agarwal Gaurav⁶^ORCID,Larham Jemma⁴,Gray Nathanael²,Carty Oluremi⁴,Barrett Joe²,Bowcock Stella⁷^ORCID,Oppermann Udo²^ORCID,Gamble Vicky²,Cook Gordon⁸^ORCID,Kyriakou Chara⁹,Drayson Mark¹⁰^ORCID,Basu Supratik¹¹^ORCID,McDonald Sarah¹²,McKinley Shelagh¹³,Gooding Sarah⁴¹⁴^ORCID,Javaid Muhammad K.²^ORCID,Ramasamy Karthik⁴¹⁵^ORCID

Affiliation:

1. School of Public Health Imperial College London Oxford UK

2. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences University of Oxford Oxford UK

3. Bath Royal United Hospitals Oxford University Hospitals NHS Trust Bath UK

4. Department of Haematology Oxford University Hospitals NHS Trust Oxford UK

5. The Botnar Research Centre Headington UK

6. Medical Sciences Division University of Oxford Oxford UK

7. Department of Haematology King's College Hospital NHS Trust London UK

8. Leeds Institute of Clinical Trials Research University of Leeds Leeds UK

9. Department of Haematology University College London Hospitals NHS Trust London UK

10. Division of Immunity and Infection University of Birmingham Birmingham UK

11. Department of Haematology University of Wolverhampton, Royal Wolverhampton NHS Trust Wolverhampton UK

12. Blood Cancer UK London UK

13. Myeloma UK Edinburgh UK

14. MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine University of Oxford Oxford UK

15. Radcliffe Department of Medicine Oxford University Oxford UK

Abstract

AbstractObjectiveTo describe determinants of persisting humoral and cellular immune response to the second COVID‐19 vaccination among patients with myeloma.MethodsThis is a prospective, observational study utilising the RUDYstudy.org platform. Participants reported their second and third COVID‐19 vaccination dates. Myeloma patients had an Anti‐S antibody level sample taken at least 21 days after their second vaccination and a repeat sample before their third vaccination.Results60 patients provided samples at least 3 weeks (median 57.5 days) after their second vaccination and before their third vaccination (median 176.0 days after second vaccine dose). Low Anti‐S antibody levels (<50 IU/mL) doubled during this interval (p = .023) and, in the 47 participants with T‐spot data, there was a 25% increase negative T‐spot tests (p = .008). Low anti–S antibody levels prior to the third vaccination were predicted by lower Anti‐S antibody level and negative T‐spot status after the second vaccine. Independent determinants of a negative T‐spot included increasing age, previous COVID infection, high CD4 count and lower percentage change in Anti‐S antibody levels.ConclusionsNegative T‐spot results predict low Anti‐S antibody levels (<50 IU/mL) following a second COVID‐19 vaccination and a number of biomarkers predict T cell responses in myeloma patients.

Funder

Myeloma UK

National Institute for Health and Care Research

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.14143

Reference9 articles.

1. COVID symptoms, testing, shielding impact on patient‐reported outcomes and early vaccine responses in individuals with multiple myeloma

2. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

3. Immune response to COVID ‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response

4. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer